Skip to content

A clinical study on improving the detection rate and clinical staging accuracy of lymph node metastasis of gastrointestinal tumors based on a new pathologic section strategy

A clinical study on improving the detection rate and clinical staging accuracy of lymph node metastasis of gastrointestinal tumors based on a new pathologic section strategy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103150
Enrollment
Unknown
Registered
2025-05-26
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric carcinoma and Colorectal cancer

Interventions

Continuous deep sectioning group:none

Sponsors

The Seventh Affiliated Hospital Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Non-bedridden patients aged >=18 and <=75 years, regardless of gender. 2. Patients with histologically confirmed gastric cancer (including adenocarcinoma of the gastroesophageal junction) or colorectal cancer. 3. Participants voluntarily enroll in this study, demonstrate good compliance, and are willing to cooperate with follow-up.

Exclusion criteria

Exclusion criteria: 1. History of other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix. 2. Presence of uncontrolled systemic diseases, including active infections, uncontrolled hypertension, diabetes mellitus, unstable angina, congestive heart failure, myocardial infarction (within 1 year prior to treatment initiation), severe arrhythmias requiring medication, or hepatic, renal, and metabolic disorders. 3. Conditions such as dysphagia, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, or perforation. 4. Pregnant or lactating women. 5. Participants unwilling to comply with contraceptive requirements during the study period. 6. History of psychotropic drug abuse with inability to abstain, or patients with psychiatric disorders. 7. Known hypersensitivity to any chemotherapy agents that may be used in the study. 8. Patients deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
Lymph node metastasis detection rate;

Countries

China

Contacts

Public ContactZheng Yang

The Seventh Affiliated Hospital Sun Yat-sen University

yangzh25@mail.sysu.edu.cn+86 18923451062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026